Patents by Inventor Peter Frederick Juby

Peter Frederick Juby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
    Patent number: 4122274
    Abstract: A novel series of optionally substituted 3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones is provided for use as inhibitors of allergic reactions. The compounds exhibit antiallergy activity by both oral and parenteral routes of administration.
    Type: Grant
    Filed: May 25, 1977
    Date of Patent: October 24, 1978
    Assignee: Bristol-Myers Company
    Inventor: Peter Frederick Juby
  • Therapeutic agents
    Patent number: 4082751
    Abstract: A series of 2-(substituted)phenyl-5-(5-1H-tetrazolyl)pyrimidin-4(3H)-ones is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.
    Type: Grant
    Filed: December 8, 1976
    Date of Patent: April 4, 1978
    Assignee: Bristol-Myers Company
    Inventors: Peter Frederick Juby, Richard Anthony Partyka
  • Selective immunosuppressive agents
    Patent number: 4079057
    Abstract: The quinazoline derivative having the formula ##STR1## and pharmaceutically acceptable salts thereof are selective immunosuppressive agents useful in the treatment of immune complex diseases such as rheumatoid arthritis.
    Type: Grant
    Filed: May 31, 1977
    Date of Patent: March 14, 1978
    Assignee: Bristol-Myers Company
    Inventors: Peter Frederick Juby, Thomas William Hudyma
  • 1,6-Dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic acid derivatives
    Patent number: 4031093
    Abstract: A series of 1,6-dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic acid derivatives is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.
    Type: Grant
    Filed: April 23, 1976
    Date of Patent: June 21, 1977
    Assignee: Bristol-Myers Company
    Inventors: Peter Frederick Juby, Richard Anthony Partyka